[CLS] O
Selegiline O
- O
induced O
postural B
hypotension I
in O
Parkinson B
' I
s I
disease I
: O
a O
longitudinal O
study O
on O
the O
effects O
of O
drug O
withdrawal O
. O
[SEP] O

[CLS] O
CONCLUSION O
: O
This O
study O
confirms O
our O
previous O
finding O
that O
selegiline O
in O
combination O
with O
L O
- O
dopa O
is O
associated O
with O
selective O
orthostatic B
hypotension I
. O
[SEP] O

[CLS] O
In O
the O
in O
vivo O
study O
, O
the O
administration O
( O
50 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
of O
TET O
and O
FAN O
in O
mice O
showed O
the O
inhibition O
of O
thrombosis B
by O
55 O
% O
and O
35 O
% O
, O
respectively O
, O
while O
acetylsalicylic O
acid O
( O
ASA O
, O
50 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
a O
positive O
control O
, O
showed O
only O
30 O
% O
inhibition O
. O
[SEP] O

[CLS] O
The O
prevalence O
rate O
for O
CIMD B
was O
12 O
% O
at O
baseline O
. O
[SEP] O

[CLS] O
Recent O
reports O
indicate O
that O
single O
agent O
therapy O
with O
vinorelbine O
( O
VNB O
) O
or O
gemcitabine O
( O
GEM O
) O
may O
obtain O
a O
response O
rate O
of O
20 O
- O
30 O
% O
in O
elderly O
patients O
, O
with O
acceptable O
toxicity B
and O
improvement O
in O
symptoms O
and O
quality O
of O
life O
. O
[SEP] O

[CLS] O
Warfarin O
- O
induced O
artery B
calcification I
is O
accelerated O
by O
growth O
and O
vitamin O
D O
. O
[SEP] O

[CLS] O
High O
doses O
of O
vitamin O
D O
are O
known O
to O
cause O
calcification B
of I
the I
artery I
media O
in O
as O
little O
as O
3 O
to O
4 O
days O
. O
[SEP] O

[CLS] O
Tamoxifen O
( O
TAM O
) O
, O
the O
antiestrogenic O
drug O
most O
widely O
prescribed O
in O
the O
chemotherapy O
of O
breast B
cancer I
, O
induces O
changes O
in O
normal O
discoid O
shape O
of O
erythrocytes O
and O
hemolytic B
anemia I
. O
[SEP] O

[CLS] O
This O
study O
was O
conducted O
to O
examine O
whether O
prolonged O
pretreatment O
with O
isoproterenol O
could O
abolish O
bromocriptine O
- O
induced O
tachycardia B
in O
conscious O
rats O
. O
[SEP] O

[CLS] O
The O
adjusted O
rate O
ratio O
of O
VTE B
for O
repeat O
users O
of O
third O
generation O
OC O
was O
0 O
. O
6 O
( O
95 O
% O
CI O
: O
0 O
. O
3 O
- O
1 O
. O
2 O
) O
relative O
to O
repeat O
users O
of O
second O
generation O
pills O
, O
whereas O
it O
was O
1 O
. O
3 O
( O
95 O
% O
CI O
: O
0 O
. O
7 O
- O
2 O
. O
4 O
) O
for O
switchers O
from O
second O
to O
third O
generation O
pills O
relative O
to O
switchers O
from O
third O
to O
second O
generation O
pills O
. O
[SEP] O

[CLS] O
Lidocaine O
reduced O
the O
area O
of O
punctate O
- O
evoked O
hyperalgesia B
significantly O
. O
[SEP] O

[CLS] O
The O
purpose O
of O
the O
present O
study O
was O
to O
examine O
the O
safety O
and O
efficacy O
of O
ketamine O
for O
sedation O
in O
the O
treatment O
of O
children O
' O
s O
fractures B
in O
the O
emergency O
department O
. O
[SEP] O

[CLS] O
As O
a O
result O
, O
switching O
to O
tacrolimus O
has O
been O
reported O
to O
be O
a O
viable O
therapeutic O
option O
in O
the O
setting O
of O
cyclosporine O
- O
induced O
TMA B
. O
[SEP] O

[CLS] O
Pain B
intensity O
on O
a O
0 O
to O
10 O
numerical O
scale O
; O
nausea B
and O
vomiting B
, O
drowsiness O
, O
confusion B
, O
and O
dry B
mouth I
, O
using O
a O
scale O
from O
0 O
to O
3 O
( O
not O
at O
all O
, O
slight O
, O
a O
lot O
, O
awful O
) O
; O
Mini O
- O
Mental O
State O
Examination O
( O
MMSE O
) O
( O
0 O
- O
30 O
) O
; O
and O
arterial O
pressure O
were O
recorded O
before O
administration O
of O
drugs O
( O
T0 O
) O
and O
after O
30 O
minutes O
( O
T30 O
) O
, O
60 O
minutes O
( O
T60 O
) O
, O
120 O
minutes O
( O
T120 O
) O
, O
and O
180 O
minutes O
( O
T180 O
) O
. O
[SEP] O

[CLS] O
Paclitaxel O
, O
cisplatin O
, O
and O
gemcitabine O
combination O
chemotherapy O
within O
a O
multidisciplinary O
therapeutic O
approach O
in O
metastatic O
nonsmall B
cell I
lung I
carcinoma I
. O
[SEP] O

[CLS] O
World O
Health O
Organization O
Grade O
3 O
- O
4 O
neutropenia B
and O
thrombocytopenia B
occurred O
in O
39 O
. O
9 O
% O
and O
11 O
. O
4 O
% O
of O
patients O
, O
respectively O
. O
[SEP] O

[CLS] O
In O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence B
secondary O
to O
the O
selective O
serotonin O
reuptake O
inhibitors O
paroxetine O
and O
sertraline O
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine O
. O
[SEP] O

[CLS] O
Two O
mouse O
lines O
were O
selectively O
bred O
according O
to O
their O
sensitivity O
( O
BS O
line O
) O
or O
resistance O
( O
BR O
line O
) O
to O
seizures B
induced O
by O
a O
single O
i O
. O
p O
. O
injection O
of O
methyl O
beta O
- O
carboline O
- O
3 O
- O
carboxylate O
( O
beta O
- O
CCM O
) O
, O
an O
inverse O
agonist O
of O
the O
GABA O
( O
A O
) O
receptor O
benzodiazepine O
site O
. O
[SEP] O

[CLS] O
Ultimately O
, O
an O
arteriography O
showed O
a O
70 O
- O
80 O
% O
renal B
artery I
stenosis I
. O
[SEP] O

[CLS] O
Pain B
was O
not O
explained O
by O
other O
diseases O
causing O
foot O
pain B
, O
like O
reflex B
sympathetic I
dystrophy I
, O
polyneuropathy B
, O
Morton B
' I
s I
neuralgia I
, O
gout B
, O
osteoporosis B
, O
avascular B
necrosis I
, O
intermittent B
claudication I
, O
orthopaedic O
foot B
deformities I
, O
stress B
fractures I
, O
and O
hyperparathyroidism B
. O
[SEP] O

[CLS] O
Patients O
who O
experienced O
a O
manic B
or O
hypomanic B
switch O
were O
compared O
with O
those O
who O
did O
not O
on O
several O
variables O
including O
age O
, O
sex O
, O
diagnosis O
( O
DSM B
- I
IV I
bipolar I
I I
vs O
. O
bipolar B
II I
) O
, O
number O
of O
previous O
manic B
episodes O
, O
type O
of O
antidepressant O
therapy O
used O
( O
electroconvulsive O
therapy O
vs O
. O
antidepressant O
drugs O
and O
, O
more O
particularly O
, O
selective O
serotonin O
reuptake O
inhibitors O
[ O
SSRIs O
] O
) O
, O
use O
and O
type O
of O
mood O
stabilizers O
( O
lithium O
vs O
. O
anticonvulsants O
) O
, O
and O
temperament O
of O
the O
patient O
, O
assessed O
during O
a O
normothymic O
period O
using O
the O
hyperthymia O
component O
of O
the O
Semi O
- O
structured O
Affective O
Temperament O
Interview O
. O
[SEP] O

[CLS] O
Caffeine O
- O
induced O
cardiac B
arrhythmia I
: O
an O
unrecognised O
danger O
of O
healthfood O
products O
. O
[SEP] O

[CLS] O
In O
contrast O
to O
the O
protection O
provided O
by O
the O
putative O
antagonists O
, O
the O
well O
- O
characterized O
sigma O
receptor O
agonist O
di O
- O
o O
- O
tolylguanidine O
( O
DTG O
) O
and O
the O
novel O
sigma O
receptor O
agonist O
BD1031 O
( O
3R O
- O
1 O
- O
[ O
2 O
- O
( O
3 O
, O
4 O
- O
dichlorophenyl O
) O
ethyl O
] O
- O
1 O
, O
4 O
- O
diazabicyclo O
[ O
4 O
. O
3 O
. O
0 O
] O
nonane O
) O
each O
worsened O
the O
behavioral O
toxicity B
of O
cocaine O
. O
[SEP] O

[CLS] O
The O
main O
outcome O
was O
the O
number O
of O
study O
participants O
experiencing O
akathisia B
within O
60 O
minutes O
of O
administration O
. O
[SEP] O

[CLS] O
The O
efficacy O
of O
prochlorperazine O
in O
the O
treatment O
of O
headache B
and O
nausea B
likewise O
did O
not O
appear O
to O
be O
affected O
by O
the O
rate O
of O
administration O
, O
although O
no O
formal O
statistical O
comparisons O
were O
made O
. O
[SEP] O

[CLS] O
Early O
trials O
of O
cisplatin O
and O
amifostine O
also O
suggested O
that O
the O
incidence O
and O
severity O
of O
cisplatin O
- O
induced O
nephrotoxicity B
, O
ototoxicity B
, O
and O
neuropathy B
were O
reduced O
. O
[SEP] O

